LymphoTrack® Archives

Cat #: 40880118
LymphoQuant^® B-cell Internal Control
LymphoQuant B-cell Internal Controls may be spiked into specimens to estimate the respective number of IGH clonotype equivalents present. Addition o...
View Product
Cat #: 40880128
LymphoQuant^® T-Cell Internal Control
The T-cell LymphoQuant Internal Control and T-cell LymphoTrack Low Positive Control are utilized in controlled MRD studies of TRG and TRB gene rearran...
View Product
Cat #: 71210007
LymphoTrack^® IGH FR1 Assay – S5/PGM™
This LymphoTrack IGH FR1 Assay – S5/PGM represents a significant improvement over existing clonality assays using fragment analysis as it efficient...
View Product
Cat #: 71210009
LymphoTrack^® IGH FR1 Assay Kit A – MiSeq^®
This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...
View Product
Cat #: 71210039
LymphoTrack^® IGH FR1 Assay Panel – MiSeq^®
This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...
View Product
Cat #: 71210149
LymphoTrack^® IGH FR1 Assay Panel B – MiSeq®
This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...
View Product
Cat #: 71210057
LymphoTrack^® IGH FR1/2/3 Assay – S5/PGM™
The LymphoTrack IGH FR1/2/3 Assay for the Ion S5 and PGM represents a significant improvement over existing clonality assays using fragment analysis...
View Product
Cat #: 71210129
LymphoTrack^® IGH FR1/2/3 Assay Kit A – MiSeq^®
The LymphoTrack IGH FR1/2/3 Assay for MiSeq represent a significant improvement over existing clonality assays using fragment analysis as they efficie...
View Product
Cat #: 71210139
LymphoTrack^® IGH FR1/2/3 Assay Panel – MiSeq^®
The LymphoTrack IGH FR1/2/3 Assay for MiSeq represent a significant improvement over existing clonality assays using fragment analysis as they efficie...
View Product
Cat #: 71210037
LymphoTrack^® IGH FR2 Assay – S5/PGM™
The LymphoTrack IGH FR2 Assay for the Ion PGM represents a significant improvement over existing clonality assays using fragment analysis as they ef...
View Product
Cat #: 71210089
LymphoTrack^® IGH FR2 Assay Kit A – MiSeq^®
This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...
View Product
Cat #: 71210099
LymphoTrack^® IGH FR2 Assay Panel – MiSeq^®
This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...
View Product

Now Available

Our New Document Search Feature

SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team

CONTACT CUSTOMER SERVICE ⟶

Now Available

Our New Document Search Feature

SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team

CONTACT CUSTOMER SERVICE ⟶

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing